Sutro Biopharma Announces STRO-002 FDA Fast Track Designation for Patients with Advanced Ovarian Cancer
Sutro Biopharma today announced that the U.S.FDA has granted Fast Track designation for STRO-002, a folate receptor alpha (FolRα)-targeting antibody-drug conjugate (ADC).
August 25, 2021
by drugs
Sutro Biopharma Announces Interim Data on STRO-002 Study for Ovarian Cancer
Sutro Biopharma has provided a clinical update from the company's ongoing dose-escalation Phase 1 study of STRO-002, a folate receptor alpha (FolRα) targeting antibody-drug conjugate (ADC), for patients with ovarian cancer.
December 24, 2020
by americanpharmaceuticalreview
Sutro Biopharma Achieves Merck KGaA Clinical Supply Milestone
Delivers GMP clinical trial supply to Merck KGaA for Phase 1 trial of M1231, a bispecific ADC for the treatment of solid tumors.
August 26, 2020
by contractpharma
Sutro Biopharma Appoints Clinical Development VP
Dr. Craig Berman has more than 17 years of experience in drug development, including immuno-oncology.
May 26, 2020
by contractpharma
Sutro Biopharma nets $85.4M to drive antibody-drug conjugates
Sutro Biopharma reeled in an $85.4 million series E that will advance some early-stage programs as well as its cancer pipeline, which includes a pair of antibody-drug conjugates (ADCs).
July 30, 2018
by fiercebiotech
Celgene opts not to acquire Sutro Biopharma for $1bn, reworks existing partnership
Celgene has announced that it has chosen not to scoop up Sutro Biopharma, rejecting to take advantage of an option outlined in its $1 billion partnership struck in 2014 which would allow it to acquire the US biotech.
August 14, 2017
by pharmafile